JP Patent

JP7584418B2 — 多重反応同位体分子種反応モニタリングによる、サンプル内検量線を用いた分析方法

Assigned to Bristol Myers Squibb Co · Expires 2024-11-15 · 2y expired

What this patent protects

Patent listed against daclatasvir-dihydrochloride.

Drugs covered by this patent

daclatasvir-dihydrochloride (DACLATASVIR DIHYDROCHLORIDE)

Patent Metadata

Patent number: JP7584418B2
Jurisdiction: JP
Classification: —
Expires: 2024-11-15
Drug substance claim: No
Drug product claim: No
Assignee: Bristol Myers Squibb Co
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.